-
Med Vision’s Sleep Disorder Software Receives Category II Approval in China
•
Hangzhou-based Med Vision, a provider of virtual reality (VR)-enabled digital therapeutics (DTx) solutions, has reportedly received a Category II medical device approval in China for its sleep disorder assisted treatment software. This marks a significant milestone as it is the first VR-based sleep disorder device to be approved both in…
-
Med Vision Secures A+ Round Financing to Accelerate Digital Therapy Commercialization
•
Hangzhou-based Med Vision Technology Co., Ltd. has successfully completed an A+ round financing, raising several tens of millions of RMB. This round was led by Hangzhou Lingxin, with existing shareholder Mifang Health Fund participating. With this financing, Med Vision has cumulatively raised over 100 million RMB in its Series A…
